Shares of Gilead Sciences Inc. GILD, -3.11% rose more than 5% in the extended session Thursday after the pharma company reported fourth-quarter earnings and sales above Wall Street expectations, sayin...
Tag: GILD
GILD Stock: Gilead Posts Its Best Growth In 7 Years As Cancer Drug Sales Rocket
Gilead Sciences (GILD) crushed fourth-quarter expectations Thursday and issued an unexpectedly bullish outlook that buoyed GILD stock. X The company hasn’t seen growth this strong since 2015 at ...
Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.
Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...
Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug
Shares of Arcus Biosciences Inc. RCUS, -27.76% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that...
GILD Stock Hits 4-Year High After Notching Another Cancer Win; RCUS Stock Surges
Gilead Sciences (GILD) and Arcus Biosciences (RCUS) notched another win for their cancer program on Monday, briefly pushing GILD stock to a four-year high as RCUS stock gapped higher. X The companies ...
GILD Stock Surges: Why Gilead Sees Its Oncology Business As A Force To Be Reckoned With
Gilead Sciences‘ (GILD) first-in-class cancer drug and GILD stock are finally hitting their stride. X The biotech company is an expert in a means of battling cancer by reprogramming a patient...
Big Pharma Stocks Are Breaking Out. Here Are Some Winners.
Big pharma stocks are trying to break out to new heights. They have reported more-than-satisfactory earnings and are expecting further progress on new pipelines of drugs. These stocks had been outpe...
GILD Stock: With A Breakout On The Line, Gilead Reports Massive Cancer Drug Sales
Gilead Sciences (GILD) crushed third-quarter expectations Thursday as sales of its cancer drugs nearly doubled. The results prodded GILD stock higher. X The bullish report follows recent approvals for...
GILD And BMY Offer A Haven In A Turbulent Market
Following another ugly market week, the average U.S. stock is now trading in Bear Market territory. Of course, such was also the case in 2020 and 2018 and 2016 and more than a few other periods throug...
Gilead’s stock is up about 4% after sharing new data for cancer drug
Shares of Gilead Sciences Inc. GILD, +5.16% were up 4.9% in trading on Monday after the company said in a news release that Trodelvy improved overall survival rates in people with HR+/HER2- metastatic...
Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
Pfizer is in advanced talks to buy Global Blood Therapeutics the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its po...
3 Healthcare Stocks With 3%+ Dividend Yields
The U.S. healthcare sector is attractive for long-term investors because the industry is set to benefit from a major growth tailwind — the aging population. The U.S. is an aging country with a v...
Humanigen’s stock tumbles 67% after sharing new clinical data for its COVID-19 treatment
Shares of Humanigen Inc. HGEN, -80.10% plunged 67.9% in premarket trading on Wednesday, the day after the company said a National Institutes of Health clinical trial testing lenzilumab and Gilead Scie...
Due diligence Can Lead Investors to Some Solid Companies With Yields of about 5%.
If a stock’s yield is around 5%, it could foreshadow a dividend cut or worse. A yield that high, however, doesn’t have to spell doom. Several investors Barron’s spoke to say they can find good opportu...
GILD Stock Dives As Two Major Issues Dig Into Fourth-Quarter Earnings
Gilead Sciences (GILD) said Tuesday its Covid treatment dragged on fourth-quarter sales as two legal charges hammered earnings — and GILD stock tumbled. X During the December quarter, sales of the Cov...